oric-114
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 10, 2022 (NCT05315700)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
ERBB2 inhibitor
EGFR inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06816992 | Phase 1 | Feb 27, 2025 | Johnson and Johnson, Oric Pharmaceuticals |
| NCT06012721 | Phase 1 | Sep 11, 2023 | Oric Pharmaceuticals |
| NCT05315700 | Phase 1 | Mar 10, 2022 | Oric Pharmaceuticals |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Oric Pharmaceuticals | For profit | 3 | 3 | 1 | 2022 |
| Johnson and Johnson | For profit | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1